February 26, 2019
PRINCETON, N.J., February 26, 2019 – FLG Partner’s client, Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company has announced a $93 million Series B financing. The round was co-led by Invus Opportunities and Flying L Partners in collaboration with Falcon Vision. Existing investors New Enterprise Associates (NEA) and Versant Ventures, as well as new investor Vida Ventures, participated significantly in the round.
An estimated 16 million U.S. adults have been diagnosed with Dry Eye Disease, a multifactorial condition of the ocular surface.1,2 Loss of tear film homeostasis is a unifying characteristic for all patients with Dry Eye Disease. 2 Oyster Point will use the proceeds of their raise to support the development of its product portfolio for Dry Eye Disease which advances to Phase 3 clinical trials, explore new treatment areas, and add key talent.
Read the full press release.